$GOVX Will probably be somewhat disappointed tomorrow if you are expecting anything more than the status quo for earnings. HOWEVER, the key here is that their phase 2 covid trial should have some results soon. All they have to do is be as good as Pfizer now, since people are tired of the MRNAs. Also, the added benefit of immunity from Monkeypox due to the MVA technology could make it a true 2nd generation vaccine. Hold tight. Risk/Reward still beneficial. Holding stock and warrants. OG here.
3
5